{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:15:16Z","timestamp":1790007316814,"version":"4.0.1"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,6,27]]},"DOI":"10.18632\/oncotarget.14917","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T20:20:36Z","timestamp":1485980436000},"page":"42007-42019","source":"Crossref","is-referenced-by-count":19,"title":["Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma"],"prefix":"10.18632","volume":"8","author":[{"given":"Yuanji","family":"Xu","sequence":"first","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China"},{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunbin","family":"Ye","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Laboratory of Immuno-Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Department of Pathology, Fujian Provincial Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Department of Pathology, Fujian Provincial Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Liao","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Department of Pathology, Fujian Provincial Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China"},{"name":"Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China"},{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China"},{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Lin","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China"},{"name":"Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China"},{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology and The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianji","family":"Pan","sequence":"additional","affiliation":[{"name":"Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China"},{"name":"Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China"},{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of nasopharyngeal carcinoma: current practice and future perspective","volume":"33","author":"Chan","year":"2015","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2010.09.011","article-title":"Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone","volume":"82","author":"Lu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.radonc.2014.05.005","article-title":"Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study","volume":"112","author":"Zhang","year":"2014","journal-title":"Radiother Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2014.02.003","article-title":"Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era","volume":"110","author":"Yeung","year":"2014","journal-title":"Radiother Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.radonc.2014.01.011","article-title":"Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin","volume":"110","author":"Lu","year":"2014","journal-title":"Radiother Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.oraloncology.2014.10.012","article-title":"Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma: validation of the 7th edition AJCC staging system","volume":"51","author":"Pan","year":"2015","journal-title":"Oral Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Smyth","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14728222.2012.681378","article-title":"Targeting NKG2D in tumor surveillance","volume":"16","author":"Hayakawa","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ijc.28775","article-title":"NKG2D signaling in cancer immunosurveillance","volume":"136","author":"Gonzalez","year":"2015","journal-title":"Int J Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4161\/cbt.2.4.479","article-title":"A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells","volume":"2","author":"Levine","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2008-12-196287","article-title":"The NKG2D ligand ULBP4 binds to TCRgamma9\/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D","volume":"114","author":"He","year":"2009","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.humimm.2006.02.015","article-title":"Regulation of NKG2D ligand gene expression","volume":"67","author":"Trowsdale","year":"2006","journal-title":"Hum Immunol"},{"key":"14","first-page":"1","article-title":"MICA\/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer","volume":"14","author":"Kim","year":"2014","journal-title":"BMC Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0006-291X(03)00714-9","article-title":"ULBP4 is a novel ligand for human NKG2D","volume":"305","author":"Cosman","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4049\/jimmunol.173.2.1078","article-title":"Two human ULBP\/RAET1 molecules with transmembrane regions are ligands for NKG2D","volume":"173","author":"Trowsdale","year":"2004","journal-title":"J Immunol"},{"key":"17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.2910170102","article-title":"Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma","volume":"17","author":"Henle","year":"1976","journal-title":"Int J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-09-0991","article-title":"NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting","volume":"15","author":"Durrant","year":"2009","journal-title":"Clin Cancer Res"},{"key":"19","first-page":"1412","article-title":"prognosis in ovarian cancer patients","volume":"127","author":"Durrant","year":"2010","journal-title":"Int J Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2407-12-24","article-title":"NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study","volume":"12","author":"Kuppen","year":"2012","journal-title":"BMC Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Compton","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/COC.0b013e31828f5c96","article-title":"A comparison between the Chinese 2008 and the 7th edition AJCC staging systems for nasopharyngeal carcinoma","volume":"38","author":"Lu","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s11427-011-4223-5","article-title":"Nasopharyngeal carcinoma: advances in genomics and molecular genetics","volume":"54","author":"Li","year":"2011","journal-title":"Sci China Life Sci"},{"key":"24","doi-asserted-by":"publisher","first-page":"36783","DOI":"10.18632\/oncotarget.9170","article-title":"Epsetin-Barr virus encoded miR-BART11 promotes inflammation induced carcinogenesis by targeting FOXP1","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"crossref","first-page":"18922","DOI":"10.1074\/jbc.M702504200","article-title":"RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity","volume":"282","author":"He","year":"2007","journal-title":"J Biol Chem"},{"key":"26","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1093\/brain\/awl205","article-title":"TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells","volume":"129","author":"Friese","year":"2006","journal-title":"Brain"},{"key":"27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/nop009","article-title":"TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients","volume":"12","author":"Parsa","year":"2010","journal-title":"Neuro Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<396::AID-IJC11>3.0.CO;2-#","article-title":"Elevated serum levels of transforming growth factor beta1 in epstein-barr virus-associated nasopharyngeal carcinoma patients","volume":"84","author":"Ahmad","year":"1999","journal-title":"Int J Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"9781","DOI":"10.18632\/oncotarget.3382","article-title":"Flotillin-2 promotes nasopharyngeal carcinoma metastasis and is necessary for the epithelial-mesenchymal transition induced by transforming growth factor-\u03b2","volume":"6","author":"Liao","year":"2015","journal-title":"Oncotarget"},{"key":"30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","article-title":"Effect of NKG2D ligand expression on host immune responses","volume":"235","author":"Lanier","year":"2010","journal-title":"Immunol Rev"},{"key":"31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1387\/ijdb.041811af","article-title":"Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies","volume":"48","author":"L\u00f3pez-Ot\u00edn","year":"2004","journal-title":"Int J Dev Biol"},{"key":"32","first-page":"8","article-title":"NKG2D ligands as therapeutic targets","volume":"13","author":"Sentman","year":"2013","journal-title":"Cancer Immun"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T19:47:49Z","timestamp":1589140069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":32,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,6,27]]}},"alternative-id":["14917","28159927"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14917","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]}}}